Latest
Amgen product sales slip but income stays steady
Net income at biotech giant Amgen stayed flat for the third quarter, despite a slight downtick in revenues to $5.8 billion, the company reported Oct. 25. Product sales saw a slight decline, including Neupogen, Epogen and its blockbuster rheumatoid arthritis drug Enbrel, which fell 6 percent, but net income stayed steady at a little more Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
